Rongtai health(SH:603579) Huachuang Securities·2025-05-21 13:30Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [7][13]. Core Views - The company reported a revenue of 1.6 billion yuan and a net profit of 192 million yuan for 2024, reflecting a year-on-year decline of 13.9% and 5.3% respectively. The first quarter of 2025 showed a slight revenue decrease of 1.4% year-on-year [1][3]. - The company plans to distribute a cash dividend of 3.5 yuan per 10 shares, resulting in a dividend payout ratio of 59.3% for 2024 [1]. - The company is focusing on expanding its second growth curve, with new product launches and technological advancements in areas such as AI and automotive seating [7]. Financial Performance Summary - For 2024, the company achieved total revenue of 1,597 million yuan, with a projected growth of 4.2% in 2025, reaching 1,664 million yuan. The net profit is expected to grow to 200 million yuan in 2025, reflecting a 4.0% increase [3][8]. - The gross margin for 2024 was reported at 31.7%, with an improvement expected in 2025 [7]. - The company’s earnings per share (EPS) for 2024 is projected at 1.08 yuan, with a gradual increase to 1.48 yuan by 2027 [3][8]. Market and Product Insights - The sales of massage chairs and small massage appliances faced challenges in 2024, with revenues declining by 14.1% and 28.6% respectively. However, the first quarter of 2025 showed signs of recovery in the domestic and Korean markets, with revenue growth of approximately 8% and 25% [7]. - The company is leveraging AI technology in its new product line, RT8900AI, which is expected to enhance its competitive edge in the market [7]. Valuation and Price Target - The target price for the company's stock is set at 31.5 yuan, based on a price-to-earnings (P/E) ratio of 28 times for 2025 [7].